Ctrl

K

Imiglucerase

Class
Lysosomal modulators
Subclass
Enzyme replacement therapies
Generic name
Imiglucerase
Brand names
Cerezyme®
Common formulations
Powder for parenteral solution
Indications for use
Labeled indications
Adults
•
Treatment of Gaucher disease type 1
Children
•
Treatment of Gaucher disease type 1
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: B2
•
Use only if benefits outweigh potential risks. Animal studies have not been reported.
•
No data is available to indicate malformation toxicity to the fetus.
•
Patients with Gaucher disease who become pregnant may experience a period of increased disease activity during pregnancy and the puerperium, including an increased risk of skeletal manifestations, exacerbation of cytopenia, hemorrhage, and an increased need for transfusion.
•
There are no controlled data in human pregnancy.
•
Treatment-naive women should consider beginning therapy prior to conception to attain optimal health and to consider continuing treatment throughout pregnancy.
•
Close monitoring of the pregnancy and clinical manifestations of Gaucher disease is necessary for the individualization of dose per the patient's needs and therapeutic response.
Breastfeeding
Acceptable for use during breastfeeding.
Unknown drug levels in breastfed infants.
No overt adverse effects reported in breastfed infants.
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource